To evaluate the role of CD8+ T-cells in the anti-tumor effect of the combination treatment, a neutralizing Ab against CD8+ T-cells was injected into SL4-inoculated mice prior to administering the PRI-724 and PD-L1 Ab combination treatment. The gene discussed is CD8A; the disease is neoplasm.